Is Eli Lilly's Management Charting the Right Course?

In the following video, Motley Fool healthcare analyst David Williamson takes a look at Eli Lilly's  CEO, John Lechleiter, examining both how his background as a scientist makes him an a rarity in big pharma and highlighting his rise to the top of Eli Lilly. David then tells investors why Lechleiter's background is both a strength for the company -- and a potential weakness.

Is Eli Lilly a buy or sell?
With two of its top three drugs poised to lose patent protection this year, is Eli Lilly a dividend stock headed nowhere fast? In a new premium report, The Motley Fool's senior pharmaceuticals analyst breaks down all of Lilly's moving parts, including an in-depth analysis of the company's must-know opportunities and reasons to buy and sell today. To find out more click here to claim your copy today.


The article Is Eli Lilly's Management Charting the Right Course? originally appeared on Fool.com.

David Williamson owns shares of Pfizer. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Socially Responsible Investing

Invest in companies with a conscience.

View Course »

Investing in Emerging Markets

Learn to invest in a globalized world.

View Course »

Add a Comment

*0 / 3000 Character Maximum